Home/Filings/4/0001415889-25-008796
4//SEC Filing

Karas Eric 4

Accession 0001415889-25-008796

CIK 0001671858other

Filed

Mar 20, 8:00 PM ET

Accepted

Mar 21, 6:30 PM ET

Size

8.7 KB

Accession

0001415889-25-008796

Insider Transaction Report

Form 4
Period: 2025-03-20
Karas Eric
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-20$1.50/sh+10,000$15,00017,696 total
  • Sale

    Common Stock

    2025-03-20$14.00/sh10,000$140,0007,696 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-03-2010,000574,588 total
    Exercise: $1.50Exp: 2032-05-23Common Stock (10,000 underlying)
Footnotes (3)
  • [F1]Includes 2,003 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
  • [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
  • [F3]Immediately exercisable.

Issuer

ARS Pharmaceuticals, Inc.

CIK 0001671858

Entity typeother

Related Parties

1
  • filerCIK 0001951287

Filing Metadata

Form type
4
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 6:30 PM ET
Size
8.7 KB